Side Effects of Nexium (Esomeprazole)
Nexium can cause both common and serious side effects, with the most frequent being headache, diarrhea, nausea, gas, abdominal pain, constipation, and dry mouth, while serious risks include acute kidney injury, severe diarrhea from C. difficile infection, bone fractures with long-term use, and rare severe skin reactions. 1
Common Side Effects
The most frequently reported adverse effects include 1:
- Headache (most common)
- Diarrhea
- Nausea
- Gas
- Abdominal pain
- Constipation
- Dry mouth
Real-world data from prescription-event monitoring of 11,595 patients confirms diarrhea as the most common event in the first month of treatment, along with nausea/vomiting, abdominal pain, dyspepsia, headache/migraine, and pruritus 2. These events occurred significantly more often in month 1 compared to months 2-6, suggesting early adaptation or intolerance issues.
Serious Side Effects Requiring Immediate Medical Attention
Kidney Problems
Acute tubulointerstitial nephritis can occur at any time during treatment. Call your doctor immediately if you experience decreased urination or blood in urine 1. Recent pharmacovigilance data shows renal and urinary adverse events had the highest frequency and strongest signal strength, with nephrogenic anemia showing particularly high signal strength 3.
Severe Infections
C. difficile-associated diarrhea can develop with PPI use. Seek immediate care for watery stools or persistent stomach pain, with or without fever 1.
Bone Fractures
Long-term use (≥1 year) and multiple daily doses increase risk of hip, wrist, or spine fractures. This risk is dose- and duration-dependent, though intermittent OTC use at lower doses carries minimal risk 4, 1.
Lupus-Related Conditions
PPIs can trigger cutaneous or systemic lupus erythematosus or worsen existing lupus. Report new or worsening joint pain or sun-sensitive rashes on cheeks or arms immediately 1.
Severe Skin Reactions
Rare but potentially life-threatening skin reactions include 1:
- Blistering, peeling, or bleeding skin
- Rash affecting lips, eyes, mouth, nose, genitals, hands, or feet
- Associated fever, chills, body aches, shortness of breath, or enlarged lymph nodes
Stop Nexium immediately and seek emergency care if these occur.
Metabolic and Nutritional Effects
Vitamin B12 Deficiency
Occurs with prolonged use (>3 years). Watch for 1:
- Shortness of breath
- Lightheadedness
- Irregular heartbeat
- Muscle weakness
- Pale skin
- Fatigue
- Mood changes
- Tingling or numbness in arms and legs
Hypomagnesemia
Can develop after ≥3 months of use. Report 1:
- Seizures
- Dizziness
- Irregular heartbeat
- Jitteriness
- Muscle aches or weakness
- Spasms of hands, feet, or voice
Important caveat: Guidelines indicate that baseline monitoring of iron, calcium, magnesium, and vitamin B12 is not necessary for OTC PPI users, as intermittent use has minimal effect on micronutrient absorption 4. However, the FDA specifically warns about hypomagnesemia with long-term prescription use.
Other Metabolic Concerns
Recent data identified unexpected signals for 3:
- Rebound acid hypersecretion
- Hyperparathyroidism secondary
Age-Specific Considerations
Elderly Patients
Adverse events concentrate in the gastrointestinal system, with dyspepsia and hyponatremia being most common 3.
Pediatric Patients
Unexpected adverse events in children include 3:
- Vomiting
- Acute kidney injury
- Anaphylactic reaction
Japanese pediatric data (ages 1-14) showed 66% reported ≥1 adverse events, though most were mild and the safety profile was similar to adults 5.
Additional Risks
Fundic Gland Polyps
Long-term PPI use (>1 year) increases risk of benign stomach growths 1.
Drug Interactions
Nexium can interact with rilpivirine, clopidogrel, St. John's Wort, rifampin, and high-dose methotrexate 1. Report these medications to your healthcare provider.
Clinical Context
The overall safety profile remains favorable. Esomeprazole is generally well-tolerated with an adverse event spectrum similar to other PPIs 6, 7. Prescription-event monitoring data confirms the safety profile is consistent with prescribing information 2. However, the emergence of new signals from real-world pharmacovigilance data—particularly renal adverse events—warrants heightened clinical awareness 3.
Key pitfall to avoid: Don't dismiss early gastrointestinal symptoms as necessarily benign—they may represent intolerance requiring dose adjustment or discontinuation, particularly in the first month of therapy 2.